secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2026-06-25T13:37:03+00:00
Accession:  0001213900-26-071804
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences to merge with Noble Africa (ASP Isotopes sub); raise $50M
-----------------------------------------------------------------------------

- Proposed merger of ENDRA subsidiary with Noble Africa LLC; combined entity Noble Africa Inc. to trade as NOBA.
- Concurrent private placement to raise ~$50M gross; ASP Isotopes commits ~$20M, other investors ~$30M.
- ASP Isotopes expected to own ~89% of combined company; ENDRA stockholders ~3%; other PIPE investors ~7%.
- Transaction approved by both boards; expected close Q3/Q4 2026, subject to SEC registration and ENDRA stockholder approval.
- Combined company led by Paul Mann (CEO of Renergen/ASP Isotopes) and Nick Mitchell; board with 5 ASPI designees, 1 ENDRA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000121390026071804/0001213900-26-071804-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000121390026071804/ea0295899-8k425_endra.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-071804

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer